Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis.
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
To compare effects of insulin-like growth factor I (IGF-I) and placebo treatment on lesions that resemble those seen during active demyelination in multiple sclerosis, we induced experimental autoimmune encephalomyelitis in Lewis rats with an emulsion containing guinea pig spinal cord and Freund's adjuvant. On day 12-13, pairs of rats with the same degree of weakness were given either IGF-I or placebo intravenously twice daily for 8 days. After 8 days of placebo or IGF-I (200 micrograms/day or 1 mg/day) treatment, the spinal cord lesions were studied by in situ hybridization and with immunocytochemical and morphological methods. IGF-I produced significant reductions in numbers and areas of demyelinating lesions. These lesions contained axons surrounded by regenerating myelin segments instead of demyelinated axons seen in the placebo-treated rats. Relative mRNA levels for myelin basic protein, proteolipid protein (PLP), and 2',3'-cyclic nucleotide 3'-phosphodiesterase in lesions of IGF-I-treated rats were significantly higher than they were in placebo-treated rats. PLP mRNA-containing oligodendroglia also were more numerous and relative PLP mRNA levels per oligodendrocyte were higher in lesions of IGF-I-treated rats. Finally, a significantly higher proportion of proliferating cells were oligodendroglia-like cells in lesions of IGF-I-treated rats. We think that IGF-I effects on oligodendrocytes, myelin protein synthesis, and myelin regeneration reduced lesion severity and promoted clinical recovery in this experimental autoimmune encephalomyelitis model. These IGF-I actions may also benefit patients with multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple extracellular signals are required for long-term oligodendrocyte survival
Barres, B. A., Schmid, R., Sendnter, M., & Raff, M. C. (1993) · Development · doi:10.1242/dev.118.1.283 · Cited by 712
Beck, K. D., Powell-Braxtont, L., Widmer, H.-R., Valverde, J., & Hefti, F. (1995) · Neuron · doi:10.1016/0896-6273(95)90216-3 · Cited by 636
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574
Katz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387
Komoly, S., Hudson, L. D., Webster, H. D., & Bondy, C. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1894 · Cited by 223
Self-citationOligodendrocytes in the early course of multiple sclerosis
Brück, W., Schmied, M., Suchanek, G., Brück, Y., Breitschopf, H., Poser, S., Piddlesden, S., & Lassmann, H. (1994) · Annals of Neurology · doi:10.1002/ana.410350111 · Cited by 216
Mozell, R. L., & McMorris, F. A. (1991) · Journal of Neuroscience Research · doi:10.1002/jnr.490300214 · Cited by 170
Cited by
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
Why does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain
Russo, V. C., Gluckman, P. D., Feldman, E. L., & Werther, G. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0024 · Cited by 492
The role of the insulin-like growth factors in the central nervous system
D’Ercole, A. J., Ye, P., Calikoglu, A. S., & Gutierrez-Ospina, G. (1996) · Molecular Neurobiology · doi:10.1007/bf02740625 · Cited by 447
ProNGF Induces p75-Mediated Death of Oligodendrocytes following Spinal Cord Injury
Beattie, M. S., Harrington, A. W., Lee, R., Kim, J. Y., Boyce, S. L., Longo, F. M., Bresnahan, J. C., Hempstead, B. L., & Yoon, S. O. (2002) · Neuron · doi:10.1016/s0896-6273(02)01005-x · Cited by 414
Linker, R. A., Mäurer, M., Gaupp, S., Martini, R., Holtmann, B., Giess, R., Rieckmann, P., Lassmann, H., Toyka, K. V., Sendtner, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0602-620 · Cited by 398
Dyer, A. H., Vahdatpour, C., Sanfeliu, A., & Tropea, D. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.056 · Cited by 377
Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned
Gudi, V., Gingele, S., Skripuletz, T., & Stangel, M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00073 · Cited by 430
“The involvement of IGF-1 in de- and remyelination has been reported for various experimental demyelination models (Yao et al., 1995; Hinks and Franklin, 1999; Mason et al., 2000b, 2003).”
BackgroundWoodruff, R. H., Fruttiger, M., Richardson, W. D., & Franklin, R. J. M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.10.014 · Cited by 335
Clark, R. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.2.0296 · Cited by 314
“For example, the hypomyelination in the IGF-I null mouse (286) and the re-myelination in damaged tissue in animal models of multiple sclerosis (287) suggest that IGF-I might be useful for the treatment for multiple sclerosis.”
BackgroundKerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H., & Hohlfeld, R. (2003) · Annals of Neurology · doi:10.1002/ana.10446 · Cited by 273
Human conditions of insulin-like growth factor-I (IGF-I) deficiency
Puche, J. E., & Castilla-Cortázar, I. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-224 · Cited by 268
Smith, T. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002469 · Cited by 267
Insulin-like growth factor 1 regulates developing brain glucose metabolism
Cheng, C. M., Reinhardt, R. R., Lee, W.-H., Joncas, G., Patel, S. C., & Bondy, C. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170008497 · Cited by 204
Remyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Macrophages in CNS remyelination: friend or foe?
Diemel, L. T., Copelman, C. A., & Cuzner, M. L. (1998) · Neurochemical Research · doi:10.1023/a:1022405516630 · Cited by 78
“Direct evidence that growth factors are involved in CNS remyelination is scarce although exogenous IGF-I supplementation enhances remyelination following demyelinating insult in EAE, cryogenic injury in spinal cord and cuprizone intoxication ( 59-61 ).”
BackgroundThe expression of myelin protein mRNAs during remyelination of lysolecithin‐induced demyelination
Woodruff, & Franklin (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00172.x · Cited by 66
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Sabo, J. K., Aumann, T. D., Kilpatrick, T. J., & Cate, H. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063415 · Cited by 13
White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
García-Domínguez, M. (2025) · Cells · doi:10.3390/cells14181408 · Cited by 13
“Pharmacological manipulation of this pathway has shown efficacy in promoting remyelination in some experimental demyelination models (Table 2) [205–207].”
Scalabrino, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040815 · Cited by 10
Metadata
- Authors
- Yao, D. L., Liu, X., Hudson, L. D., & Webster, H. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-06-20
- Volume
- 92
- Issue
- 13
- Pages
- 6190-6194
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2010475095
- Cited by
- 215
- References
- 8
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.